Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Aquestive Therapeutics ( (AQST) ) has provided an announcement.
Aquestive Therapeutics has announced updates regarding its product pipeline, particularly the advancement of Anaphylm (dibutepinephrine) Sublingual Film and other candidates like AQST-108 and Libervant. The company is working towards FDA approval and international market entry, with potential implications for its market positioning and stakeholder interests, contingent on overcoming regulatory and competitive challenges.
The most recent analyst rating on (AQST) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Aquestive Therapeutics stock, see the AQST Stock Forecast page.
Spark’s Take on AQST Stock
According to Spark, TipRanks’ AI Analyst, AQST is a Neutral.
Aquestive Therapeutics’ overall stock score is primarily impacted by its financial performance, which poses significant risks due to declining revenues and high leverage. While technical analysis shows strong bullish momentum, the valuation remains challenged by ongoing losses. The earnings call provided some positive developments, but financial and market access challenges persist.
To see Spark’s full report on AQST stock, click here.
More about Aquestive Therapeutics
Aquestive Therapeutics, Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of innovative drug delivery systems. The company specializes in oral film-based medications, with a market focus on providing alternatives to traditional drug administration methods.
Average Trading Volume: 3,015,806
Technical Sentiment Signal: Buy
Current Market Cap: $735.5M
See more data about AQST stock on TipRanks’ Stock Analysis page.